YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome



To investigate the YKL-40, as a marker of inflammation, in aqueous humor and serum of cataract patients with and without pseudoexfoliation syndrome (PEX).


Aqueous humor and serum samples were obtained from 44 patients who underwent phacoemulsification surgery. All patients were divided into two groups: PEX (n = 24) and control (n = 20). YKL-40 levels were measured with enzyme-linked immunosorbent assay (ELISA). The differences between the groups were assessed by using Chi-square and independent sample t-tests. The Pearson correlation coefficient was used to evaluate the correlation between variables.


There was a significant difference between the mean YKL-40 levels in the aqueous humor of PEX group (112.0 ± 35.8 ng/mL) and control subjects (88.2 ± 30.6 ng/mL) (P = 0.025). However, the difference between the mean YKL-40 levels in the serum of PEX group (53.5 ± 29.1 ng/mL) and control subjects (44.6 ± 30.2 ng/mL) was non-significant (P = 0.326). The correlation between aqueous humor and serum YKL-40 concentrations was significant in both the groups (r = 0.833, P < 0.001; r = 0.840, P < 0.001, respectively).


Increased aqueous humor levels of YKL-40 demonstrate that it is local, but not a systemic marker for inflammation in patients with PEX.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1


  1. 1.

    Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol. 2001;45:265–315.

  2. 2.

    Streeten BW, Li ZY, Wallace RN, Eagle RC Jr, Keshgegian AA. Pseudoexfoliative fibrillopathy in visceral organs of a patient with pseudoexfoliation syndrome. Arch Ophthalmol. 1992;110:1757–62.

  3. 3.

    Helbig H, Schlötzer-Schrehardt U, Noske W, Kellner U, Foerster MH, Naumann GOH. Anterior-chamber hypoxia and iris vasculopathy in pseudoexfoliation syndrome. Ger J Ophthalmol. 1994;3:148–53.

  4. 4.

    Schlötzer-Schrehardt U. Oxidative stress and pseudoexfoliation glaucoma. Klin Monbl Augenheilkd. 2010;227:108–13.

  5. 5.

    Zenkel M, Lewczuk P, Jünemann A, Kruse FE, Naumann GO, Schlötzer-Schrehardt U. Proinflammatory cytokines are involved in the initiation of the abnormal matrix process in pseudoexfoliation syndrome/glaucoma. Am J Pathol. 2010;176:2868–79.

  6. 6.

    Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag. 2015;11:359–70.

  7. 7.

    Chupp GL, Lee CG, Jar jour N, Shim YM, Holm CT, He S, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med. 2007;357:2016–27.

  8. 8.

    Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res. 1999;250:168–73.

  9. 9.

    Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem. 1993;268:25803–10.

  10. 10.

    Shackelton LM, Mann DM, Millis AJ. Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J Biol Chem. 1995;270:13076–83.

  11. 11.

    Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39(CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–5.

  12. 12.

    Rathcke CN, Vestergaard H. YKL-40-an emerging biomarker in cardiovascular disease and diabetes. Cardiovasc Diabetol. 2009;8:61.

  13. 13.

    Nielsen AR, Plomgaard P, Krabbe KS, Johansen JS, Pedersen BK. IL-6, but not TNF-α, increases plasma YKL- 40 in human subjects. Cytokine. 2011;55:152–5.

  14. 14.

    Michelsen AE, Rathcke CN, Skjelland M, Holm S, Ranheim T, Krohg-Sørensen K, et al. Increased YKL-40 expression in patients with carotid atherosclerosis. Atherosclerosis. 2010;211:589–95.

  15. 15.

    Kim HM, Lee BW, Song YM, Kim WJ, Chang HJ, Choi DHP, et al. Potential association between coronary artery disease and the inflammatory biomarker YKL-40 in asymptomatic patients with type 2 diabetes mellitus. Cardiovasc Diabetol. 2012;11:84.

  16. 16.

    Väänänen T, Koskinen A, Paukkeri EL, Hämäläinen M, Moilanen T, Moilanen E, et al. YKL-40 as a novel factor associated with inflammation and catabolic mechanisms in osteoarthritic joints. Mediat Inflamm. 2014;2014:215140.

  17. 17.

    Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172–209.

  18. 18.

    Seo J, Ahn Y, Zheng Z, Kim BO, Choi MJ, Bang D, et al. Clinical significance of serum YKL-40 in Behçet disease. Br J Dermatol. 2016;174:1337–44.

  19. 19.

    Yildirim Z, Yildirim F, Uçgun NI, Sepici-Dinçel A. The role of the cytokines in the pathogenesis of pseudoexfoliation syndrome. Int J Ophthalmol. 2013;6:50–53.

  20. 20.

    Garweg JG, Zandi S, Pfister IB, Skowronska M, Gerhardt C. Comparison of cytokine profiles in the aqueous humor of eyes with pseudoexfoliation syndrome and glaucoma. PLoS One. 2017;12:e0182571.

  21. 21.

    Sarenac Vulovic TS, Pavlovic SM, Zdravkovic NS. Proinflammatory Cytokines Induce XFG Development. Ocul Immunol Inflamm. 2016;24:671–7.

  22. 22.

    Sarenac Vulovic TS, Pavlovic SM, Jakovljevic VL, Janicijevic KB, Zdravkovic NS. Nitric oxide and tumour necrosis factor alpha in the process of pseudoexfoliation glaucoma. Int J Ophthalmol. 2016;9:1138–42.

  23. 23.

    Rathcke CN, Vestergaard H. YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis. Inflamm Res. 2006;55:221–7.

  24. 24.

    Hirano T, Matsuda T, Nakajima K. Signal transduction through gp130 that is shared among the receptors for the interleukin 6 related cytokine subfamily. Stem Cells. 1994;12:262–77.

  25. 25.

    Påhlman LI, Jögi A, Gram M, Mori M, Egesten A. Hypoxia down-regulates expression of secretory leukocyte protease inhibitor in bronchial epithelial cells via TGF-β1. BMC Pulm Med. 2015;15:19.

  26. 26.

    Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S. Serum YKL- 40 levels in patients with coronary artery disease. Coron Artery Dis. 2007;18:391–6.

  27. 27.

    Wang Y, Ripa RS, Johansen JS, Gabrielsen A, Steinbruchel DA, Friis T, et al. YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand Cardiovasc J. 2008;42:295–302.

  28. 28.

    Celik C, Abali R, Guzel S, Bastu E, Kucukyalcin V, Yilmaz M. Elevated circulating levels of YKL-40 are a marker of abnormal glucose tolerance in women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 2012;77:893–7.

  29. 29.

    Mitchell P, Wang JJ, Smith W. Association of pseudoexfoliation syndrome with increased vascular risk. Am J Ophthalmol. 1997;124:685–7.

  30. 30.

    Schlötzer-Schrehardt UM, Koca MR, Naumann GO, Volkholz H. Pseudoexfoliation syndrome. Ocular manifestation of a systemic disorder?. Arch Ophthalmol. 1992;110:1752–6.

  31. 31.

    Gonen KA, Gonen T, Gumus B. Renal artery stenosis and abdominal aorta aneurysm in patients with pseudoexfoliation syndrome. Eye (Lond). 2013;27:735–41.

  32. 32.

    Praveen MR, Shah SK, Vasavada AR, Diwan RP, Shah SM, Zumkhawala BR, et al. Pseudoexfoliation as a risk factor for peripheral vascular disease: a case-control study. Eye (Lond). 2011;25:174–9.

  33. 33.

    Türkyılmaz K, Öner V, Kırbas A, Sevim MS, Sekeryapan B, Özgür G, et al. Serum YKL-40 levels as a novel marker of inflammation and endothelial dysfunction in patients with pseudoexfoliation syndrome. Eye (Lond). 2013;27:854–9.

  34. 34.

    van Kooij B, Rothova A, Rijkers GT, de Groot-Mijnes JD. Distinct cytokine and chemokine profiles in the aqueous of patients with uveitis and cystoid macular edema. Am J Ophthalmol. 2006;142:192–4.

  35. 35.

    Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factoralpha. Biochem J. 2004;380:651–9.

  36. 36.

    Johansen JS, Lottenburger T, Nielsen HJ. Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol Biomark Prev. 2008;17:2603–8.

  37. 37.

    Knudsen LS, Hetland ML, Johansen JS, Skjødt H, Peters ND, Colic A, et al. Changes in plasma IL-6, plasma VEGF and serum YKL-40 during Treatment with Etanercept and Methotrexate or Etanercept alone in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy. Biomark Insights. 2009;4:91–95.

  38. 38.

    Gerin F, Sener U, Erman H, Yilmaz A, Aydin B, Armutcu F, et al. The effects of quercetin on acute lung injury and biomarkers of inflammation and oxidative stress in the rat model of sepsis. Inflammation. 2016;39:700–5.

  39. 39.

    Esteghamati A1, Rezvani S, Khajeh E, Ebadi M, Nakhjavani M, Noshad S. Comparative effects of metformin and pioglitazone on YKL-40 in type 2 diabetes: a randomized clinical trial. J Endocrinol Invest. 2014;37:1211–8.

  40. 40.

    Kunz LI, van’t Wout EF, van Schadewijk A, Postma DS, Kerstjens HA, Sterk PJ, et al. Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo. Respir Res. 2015;16:154.

  41. 41.

    Zhang W, Murao K, Zhang X, Matsumoto K, Diah S, Okada M, et al. Resveratrol represses YKL-40 expression in human glioma U87 cells. BMC Cancer. 2010;10:593.

  42. 42.

    Rakic JM, Lambert V, Deprez M, Foidart JM, Noël A, Munaut C. Estrogens reduce the expression of YKL-40 in the retina: implications for eye and joint diseases. Invest Ophthalmol Vis Sci. 2003; 44: 1740–6.

Download references

Author information

Correspondence to Tansu Gonen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gonen, T., Guzel, S. & Keskinbora, K.H. YKL-40 is a local marker for inflammation in patients with pseudoexfoliation syndrome. Eye 33, 772–776 (2019) doi:10.1038/s41433-018-0308-8

Download citation